Content<\/p>\n

GENOTROPIN\u00ae<\/a><\/li>\n
Warnings and Precautions<\/a><\/li>\n
3\tPreparation and Administration<\/a><\/li>\n
2\tDosing of Adult Patients<\/a><\/li>\n
Report Adverse Event<\/a><\/li>\n
Related products<\/a><\/li>\n
Find GENOTROPIN\u00ae\u00a0medical information:<\/a><\/li>\n
Important Safety Information & Indications<\/a><\/li>\n
1\tPediatric Patients<\/a><\/li>\n
Dosage and Administration<\/a><\/li>\n
Drug Interactions<\/a><\/li>\n
2\tPharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment<\/a><\/li>\n<\/ul>\n<\/div>\n
$\"genopharm$ <\/p>\n
It should be used with caution in nursing mothers because it is not known whether growth hormone is passed into human milk. Growth hormone should not be used in patients who are critically ill because of surgery, trauma, or respiratory failure. Growth hormone should not be used to increase height in children after the growth plates have closed. The display will continue to show until the battery is completely empty. Your pen can still be used correctly, but the dose size will not be displayed. The selected dose size.The number indicates the dose size (in mg) that your pen will deliver if the injection button is fully pressed in.<\/p>\n
GENOTROPIN\u00ae<\/h2>\n
$\"genopharm$ <\/p>\n
Progression of scoliosis can occur in patients who experience rapid growth. Because somatropin increases growth rate, patients with a history of scoliosis who are treated with somatropin should be monitored for progression of scoliosis. However, somatropin has not been shown to increase the occurrence of scoliosis. Skeletal abnormalities including scoliosis are commonly seen in untreated Turner syndrome patients.<\/p>\n
Warnings and Precautions<\/h3>\n
The amino acid series in Genopharm is identical to the body\u2019s naturally produced human growth hormone (HGH). In studies of GENOTROPIN in children with Turner syndrome, side effects included flu, throat, ear, or sinus infection, runny nose, joint pain, and urinary tract infection. Use a different place on the body each day for growth hormone injections. This can help to prevent skin problems such as lumpiness or soreness. Growth hormone should not be used in patients who have been recently diagnosed with cancer, with cancer, or who are being treated for cancer. So, the presence of these brain tumors should be ruled out before treatment is started.<\/p>\n
3\tPreparation and Administration<\/h3>\n
In vitro, preclinical, and clinical tests have demonstrated that GENOTROPIN lyophilized powder is therapeutically equivalent to human growth hormone of pituitary origin and achieves similar pharmacokinetic profiles in normal adults. In patients with GHD or PWS, treatment with GENOTROPIN also normalizes concentrations of IGF-I (Insulin-like Growth Factor-I\/Somatomedin C). In adults with GHD, treatment with GENOTROPIN results in reduced fat mass, increased lean body mass, metabolic alterations that include beneficial changes in lipid metabolism, and normalization of IGF-I concentrations. The safety and efficacy of GENOTROPIN in the treatment of pediatric patients born small for gestational age (SGA) were evaluated in 4 randomized, open-label, controlled clinical trials. The safety and efficacy of GENOTROPIN in the treatment of pediatric patients with Prader-Willi syndrome (PWS) were evaluated in two randomized, open-label, controlled clinical trials. Patients received either GENOTROPIN or no treatment for the first year of the studies, while all patients received GENOTROPIN during the second year.<\/p>\n
2\tDosing of Adult Patients<\/h2>\n
These effects on body composition were maintained when treatment was continued beyond 6 months. Bone mineral density declined after 6 months of treatment but returned to baseline values after 12 months of treatment. In perinatal and postnatal studies in rats, somatropin doses of 0.3, 1, and 3.3 mg\/kg\/day produced growth\u2011promoting effects in the dams but not in the fetuses.<\/p>\n
Report Adverse Event<\/h3>\n
Limited published data indicate that somatropin treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance in man. These data suggest that somatropin administration may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). Careful monitoring is advisable when somatropin is administered in combination with other drugs known to be metabolized by CYP450 liver enzymes.<\/p>\n
Related products<\/h2>\n
Patients with preexisting type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during somatropin therapy. The doses of antihyperglycemic drugs (i.e., insulin or oral\/injectable agents) may require adjustment when somatropin therapy is instituted in these patients. Non-weight based \u2014 based on published consensus guidelines, a starting dose of approximately 0.2 mg\/day (range, 0.15\u20130.30 mg\/day) may be used without consideration of body weight. The dose should be decreased as necessary on the basis of adverse events and\/or serum IGF-I concentrations above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person, and between male and female patients. Two randomized, open-label, clinical trials were conducted that evaluated the efficacy and safety of GENOTROPIN in Turner syndrome patients with short stature.<\/p>\n
Find GENOTROPIN\u00ae medical information:<\/h2>\n
Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses. GENOTROPIN cartridges contain m-Cresol and should not be used by patients allergic to it. Growth hormone should only be used during pregnancy if clearly needed.<\/p>\n
\n
This can help to prevent skin problems such as lumpiness or soreness.<\/li>\n
GENOTROPIN is a prescription product for the replacement of growth hormone in adults with growth hormone deficiency (GHD) that started either in childhood or as an adult.<\/li>\n
Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses.<\/li>\n
Do not throw away (dispose of) the needles and syringes in the household trash.<\/li>\n
In addition, patients with Turner syndrome should be monitored closely for cardiovascular disorders (e.g., stroke, aortic aneurysm\/dissection, hypertension) as these patients are also at risk for these conditions.<\/li>\n
Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs [see Contraindications (4)].<\/li>\n
If you have any questions about your dose or your treatment with GENOTROPIN, call your healthcare provider right away.<\/li>\n<\/ul>\n
Important Safety Information & Indications<\/h3>\n
\n
Patients who received GENOTROPIN showed significant increases in linear growth during the first year of study, compared with patients who received no treatment (see Table 3).<\/li>\n
Some liquid may appear from the needle tip, and the numbers may disappear from the dose display.<\/li>\n
In patients with growth hormone deficiency, central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment.<\/li>\n
In children experiencing rapid growth, limping or hip or knee pain may occur.<\/li>\n
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.<\/li>\n
This can be avoided by rotating the injection site [see Dosage and Administration (2.3)].<\/li>\n
GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.<\/li>\n
As seen in Table 6, height velocity SDS and height SDS values were smaller at baseline and after treatment with GENOTROPIN when the normative standards were utilized as opposed to the Turner syndrome standard.<\/li>\n<\/ul>\n
The linear growth response was greater in Study 055 wherein patients were treated with a larger dose of GENOTROPIN. Adult GHD patients treated with GENOTROPIN at the recommended adult dose [see Dosage and Administration (2)] demonstrate a decrease in fat mass and an increase in lean body mass. When these alterations are coupled with the increase in total body water, the overall effect of GENOTROPIN is to modify body composition, an effect that is maintained with continued treatment.<\/p>\n
1\tPediatric Patients<\/h2>\n
Generally, a dose of 0.16 to 0.24 mg\/kg body weight\/week is recommended. Other common somatropin-related adverse reactions include injection site reactions\/rashes and lipoatrophy (6.1) and headaches (6.2). You are no longer growing, so you no longer need to generate as many new cells on a regular basis. GH directly influences the growth and development of cells, bones, cartilage, muscles, skin, blood vessels, nerves, liver and kidneys.<\/p>\n
Dosage and Administration<\/h3>\n
\n
As a result, previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment.<\/li>\n
Attach the Needle Guard (Optional)The needle guard is intended to hide the needle before, during and after injection and to reduce needle injury.<\/li>\n
Non-weight based \u2014 based on published consensus guidelines, a starting dose of approximately 0.2 mg\/day (range, 0.15\u20130.30 mg\/day) may be used without consideration of body weight.<\/li>\n
GENOTROPIN was administered as a daily SC injection at a dose of 0.04 mg\/kg\/week for the first month of treatment and 0.08 mg\/kg\/week for subsequent months.<\/li>\n
Elderly patients may be more sensitive to the action of GENOTROPIN, and therefore may be more prone to develop adverse reactions.<\/li>\n
That is a direct result of shifting hormone levels, plus changes in blood pressure and skin sensitivity; all of which are governed by GH.<\/li>\n
Do not throw away (dispose of) the needles and cartridges in the household trash.<\/li>\n
Monitor patients on somatropin therapy carefully for increased growth, or potential malignant changes, of preexisting nevi.<\/li>\n<\/ul>\n
Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropins [see Warnings and Precautions (5.6)]. Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropins. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs [see Contraindications (4)]. GENOTROPIN should not be used by patients who have had an allergy or bad reaction to somatropin or any of the other ingredients in GENOTROPIN.<\/p>\n
Drug Interactions<\/h3>\n
Limited published data indicate that exogenous somatropin does not increase normal breastmilk concentrations of growth hormone. No adverse effects related to somatropin in the breastfeed infant have been reported. Slipped capital femoral epiphyses may occur more frequently in patients with endocrine disorders (including GHD and Turner syndrome) or in patients undergoing rapid growth. Any pediatric patient with the onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated. In general, somatropin is contraindicated in the presence of active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin.<\/p>\n
2\tPharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment<\/h2>\n
GENOTROPIN MUST NOT BE INJECTED if the solution is cloudy or contains particulate matter. The weekly dose should be divided into 6 or 7 subcutaneous injections. Genopharm is also termed recombined Human Growth Hormone, or rHGH ( Somatropin ).<\/p>\n
2\tPrader-Willi Syndrome (PWS)<\/h2>\n
$\"genopharm$ <\/p>\n
Treatment with GENOTROPIN did not accelerate bone age, compared with patients who received no treatment. The microsomal enzyme 11\u03b2-hydroxysteroid dehydrogenase type 1 (11\u03b2HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Consequently, individuals with untreated GH deficiency have relative increases in 11\u03b2HSD-1 and serum cortisol. Introduction of somatropin treatment may result in inhibition of 11\u03b2HSD-1 and reduced serum cortisol concentrations. As a consequence, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required in patients treated with somatropin.<\/p>\n
In renal cells, at least a portion of the breakdown products are returned to the systemic circulation. The mean terminal half-life of intravenous GENOTROPIN in normal adults is 0.4 hours, whereas subcutaneously administered GENOTROPIN has a half-life of 3.0 hours in GHD adults. The observed difference is due to slow absorption from the subcutaneous injection site. In healthy adult males, following an SC injection in the thigh of 0.03 mg\/kg, the extent of absorption (AUC) of a concentration of 5.3 mg\/mL GENOTROPIN was 35% greater than that for 1.3 mg\/mL GENOTROPIN.<\/p>\n
\n
The 5 mg and 12 mg presentations of GENOTROPIN lyophilized powder contain m-cresol as a preservative.<\/li>\n
Patients with preexisting type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during somatropin therapy.<\/li>\n
Turner syndrome patients were treated with GENOTROPIN alone or GENOTROPIN plus adjunctive hormonal therapy (ethinylestradiol or oxandrolone).<\/li>\n
Nitrogen retention, as demonstrated by decreased urinary nitrogen excretion and serum urea nitrogen, follows the initiation of therapy with GENOTROPIN.<\/li>\n
The mean clearance of subcutaneously administered GENOTROPIN in 16 GHD adult patients was 0.3 (\u00b1 0.11) L\/hrs\/kg.<\/li>\n
Linear growth is facilitated in part by increased cellular protein synthesis.<\/li>\n
In Study 2, the treatment group received GENOTROPIN at a dose of 0.36 mg\/kg\/week during the entire study.<\/li>\n<\/ul>\n
Somatropin should be discontinued if there is evidence of recurrent activity. Since growth hormone deficiency may be an early sign of the presence of a pituitary tumor (or, rarely, other brain tumors), the presence of such tumors should be ruled out prior to initiation of treatment. Somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor. Some cases of pancreatitis (inflamed pancreas) have been reported rarely in children and adults receiving growth hormone. There is some evidence that there is a greater risk of this in children than in adults. Literature suggests that girls who have Turner syndrome may have a greater risk of pancreatitis than other children taking growth hormone.<\/p>\n
In any child who develops lasting, severe abdominal pain, pancreatitis should be considered. A small number of patients treated with growth hormone have had increased pressure in the brain. Patients with Turner syndrome and Prader-Willi syndrome may be at higher risk of developing increased pressure in the brain.<\/p>\n
Similar bioavailability has been observed in healthy adult male subjects. Pediatric patients with hypopituitarism sometimes experience fasting hypoglycemia that is improved by treatment with GENOTROPIN. Somatropin is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction genopharm hgh<\/a> or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients [see Warnings and Precautions (5.2)]. Thyroid function should be checked regularly during growth hormone therapy. Thyroid hormone replacement therapy should be started or adjusted if needed.<\/p>\n
Scoliosis is also commonly seen in untreated patients with Prader-Willi syndrome. Physicians should be alert to these abnormalities, which may manifest during somatropin therapy. A lower starting dose and smaller dose increments should be considered for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen.<\/p>\n
GENOTROPIN was administered as a daily SC injection, and the dose was calculated for each patient every 3 months. In Study 1, the treatment group received GENOTROPIN at a dose of 0.24 mg\/kg\/week during the entire study. During the second year, the control group received GENOTROPIN at a dose of 0.48 mg\/kg\/week. In Study 2, the treatment group received GENOTROPIN at a dose of 0.36 mg\/kg\/week during the entire study. During the second year, the control group received GENOTROPIN at a dose of 0.36 mg\/kg\/week. Undiagnosed\/untreated hypothyroidism may prevent an optimal response to somatropin, in particular, the growth response in children.<\/p>\n","protected":false},"excerpt":{"rendered":"
Content GENOTROPIN\u00ae Warnings and Precautions 3 Preparation and Administration 2 Dosing of Adult Patients Report Adverse Event Related products Find GENOTROPIN\u00ae\u00a0medical information: Important Safety Information & Indications 1 Pediatric Patients Dosage and Administration Drug Interactions 2 Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment It should be used with caution in nursing mothers because it is […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"","ocean_second_sidebar":"","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"","ocean_custom_header_template":"","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"","ocean_menu_typo_font_family":"","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"on","ocean_gallery_id":[],"footnotes":""},"categories":[387],"tags":[],"class_list":["post-42676","post","type-post","status-publish","format-standard","hentry","category-hghworld","entry"],"_links":{"self":[{"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/posts\/42676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/comments?post=42676"}],"version-history":[{"count":0,"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/posts\/42676\/revisions"}],"wp:attachment":[{"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/media?parent=42676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/categories?post=42676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/imtes.fr\/index.php\/wp-json\/wp\/v2\/tags?post=42676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}